Coya Therapeutics announced that Arun Swaminathan has been promoted to the role of CEO effective November 1. He will succeed Howard Berman who will continue to serve in the capacity of executive chair. Coya also believes it will benefit from Swaminathan’s leadership in advancing COYA 302 in related programs such as Frontotemporal Dementia, Parkinson’s Disease and other immune mediated diseases.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA: